Aker Biomarine ASA
OSE:AKBM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.1095
59.5148
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Aker Biomarine ASA
Cash & Cash Equivalents
Aker Biomarine ASA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aker Biomarine ASA
OSE:AKBM
|
Cash & Cash Equivalents
$27.5m
|
CAGR 3-Years
45%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Orkla ASA
OSE:ORK
|
Cash & Cash Equivalents
kr1.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
Leroy Seafood Group ASA
OSE:LSG
|
Cash & Cash Equivalents
kr3.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
15%
|
|
|
SalMar ASA
OSE:SALM
|
Cash & Cash Equivalents
kr627m
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
|
Austevoll Seafood ASA
OSE:AUSS
|
Cash & Cash Equivalents
kr7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
|
Mowi ASA
OSE:MOWI
|
Cash & Cash Equivalents
€178.3m
|
CAGR 3-Years
30%
|
CAGR 5-Years
15%
|
CAGR 10-Years
2%
|
|
Aker Biomarine ASA
Glance View
Aker BioMarine AS operates as a biotech innovator and Antarctic krill-harvesting company which develops krill-based ingredients for nutraceutical, aquaculture, and animal feed applications. The company is headquartered in Lysaker, Akershus. The company went IPO on 2020-07-06. The company consists of two business segments: Ingredients and Brands. Under The Ingredients segment, the Company develops krillbased ingredients for human applications in the nutraceutical and dietary supplement space, and animal feed applications for aquaculture and pet food. Under The Brands segment, the Company has two companies: Lang Pharma Nutrition and Epion Brands. Lang Pharma Nutrition is a full service, mass market private label and corporate brand manufacturer within supplements. Epion Brands has its own consumer brand in the US market, Kori, being on the shelves of retailers. Aker BioMarine’s focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste.
See Also
What is Aker Biomarine ASA's Cash & Cash Equivalents?
Cash & Cash Equivalents
27.5m
USD
Based on the financial report for Dec 31, 2023, Aker Biomarine ASA's Cash & Cash Equivalents amounts to 27.5m USD.
What is Aker Biomarine ASA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
78%
Over the last year, the Cash & Cash Equivalents growth was 23%. The average annual Cash & Cash Equivalents growth rates for Aker Biomarine ASA have been 45% over the past three years , 78% over the past five years .
You don't have any saved screeners yet
